Olumiant® ▼ (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Olumiant Summary of Product Characteristics (SmPC)

Olumiant® ▼ (baricitinib): Switching from a Biologic DMARD to Barcitinib

Patients were switched from a bDMARD (adalimumab) to baricitinib without a washout.

Switching From Biologic DMARDs to Baricitinib in Phase 3 Studies RA-BEAM Rescue and RA-BEAM → RA-BEYOND

Over the course of the phase 3 clinical development program, patients were able to switch from a bDMARD to BARI in 2 different scenarios, described below.

In both RA-BEAM rescue and RA-BEAM → RA-BEYOND, the switch from adalimumab to BARI 4 mg occurred 14 days after the previous adalimumab dose without a required washout period per study protocol.1,2

RA-BEAM Rescue

A 52-week study, RA-BEAM, evaluated the efficacy and safety of BARI 4 mg once daily vs placebo or adalimumab 40 mg every 2 weeks, with background MTX, in patients with

  • moderate-to-severe RA, and

  • an inadequate response to MTX.3

The study was conducted using innovator adalimumab as the active comparator.3

As early as week 16, patients treated with adalimumab were eligible for rescue treatment with BARI 4 mg based on predefined criteria for inadequate response at both week 14 and week 16.3

RA-BEAM to RA-BEYOND

RA-BEYOND was a long-term extension study designed to evaluate the efficacy and safety of patients with moderate-to-severe RA enrolled from the phase 2 and phase 3 clinical studies. RA-BEYOND includes patients from RA-BEAM who switched treatment from adalimumab (52 weeks before enrolling into RA-BEYOND) to BARI 4 mg daily upon study entry.2

Patients Stopped Biologic DMARD Therapy Prior to Randomization in Phase 3 Study RA-BEACON

RA-BEACON evaluated BARI vs placebo, with background csDMARD therapy, in patients with

  • moderate-to-severe RA, and

  • an inadequate response to TNF inhibitors, a type of bDMARD therapy.4

Study Inclusion Criteria Related to Prior Biologic DMARD Therapy: RA-BEACON

In order to participate in RA-BEACON, patients stopped their bDMARD therapy at least 28 days prior to planned randomization. Biologic DMARDs included

  • etanercept

  • anakinra

  • infliximab

  • tocilizumab

  • certolizumab

  • adalimumab

  • golimumab, or

  • abatacept.1

Patients previously treated with rituximab could not have had a dose within 6 months of randomization.1

Therapeutic Indication

Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.5

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(7):890‐898. http://dx.doi.org/10.1136/annrheumdis-2018-214529

3. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652-662. http://dx.doi.org/10.1056/NEJMoa1608345

4. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243-1252. http://dx.doi.org/10.1056/NEJMoa1507247

5. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

BARI = baricitinib

bDMARD = biologic disease-modifying antirheumatic drug

csDMARD = conventional synthetic disease-modifying antirheumatic drug

DMARD = disease-modifying antirheumatic drug

MTX = methotrexate

RA = rheumatoid arthritis

TNF = tumor necrosis factor

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: May 15, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question